{"content":"<li class=\"n-box-item date-title\" data-end=\"1505879999\" data-start=\"1505793600\" data-txt=\"Monday, December 23, 2019\">Tuesday, September 19, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3296493\" data-ts=\"1505863553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/T\" target=\"_blank\">T</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296493-texas-becomes-largest-state-to-opt-in-to-and-ts-firstnet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas becomes largest state to opt in to AT&amp;T&#39;s FirstNet</a></h4><ul>   <li>Texas has joined the list of states <a href=\"https://seekingalpha.com/pr/16945556-texas-transform-communications-public-safety-governor-abbott-approves-buildout-plan-first\" target=\"_blank\">opting into AT&amp;T's FirstNet</a> infrastructure for first responders.</li>    <li>The move isn't a surprise, but it's the largest state yet and follows opt-ins by Idaho and Maryland and could add momentum to the effort.</li>    <li>The states opting in enter a public-private partnership where AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color='green'>+2.1%</font>) builds, operates and maintains a priority network for first responders including police, firefights and emergency medical personnel.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296493\" data-linked=\"Texas becomes largest state to opt in to AT&amp;T&#39;s FirstNet\" data-tweet=\"$T - Texas becomes largest state to opt in to AT&amp;T&#39;s FirstNet https://seekingalpha.com/news/3296493-texas-becomes-largest-state-to-opt-in-to-and-ts-firstnet?source=tweet\" data-url=\"https://seekingalpha.com/news/3296493-texas-becomes-largest-state-to-opt-in-to-and-ts-firstnet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296488\" data-ts=\"1505861200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHCP\" target=\"_blank\">DHCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296488-walter-investmentplus-52-barclays-boosts-financing-commitment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Walter Investment +52% as Barclays boosts financing commitment</a></h4><ul>     <li>Walter Investment Management (WAC) <font color='green'>+52.3%</font> AH after soaring 40% in regular trading on news it entered into a commitment letter with Barclays, who has agreed to <a href=\"https://seekingalpha.com/filing/3701684\" target=\"_blank\">increase financing</a> available to the company.</li>     <li>Barclays will provide WAC with an upsize of the facilities with a maximum $300M increase amount, which the company hopes will help ensure it has sufficient liquidity in the near-term.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3296488\" data-linked=\"Walter Investment +52% as Barclays boosts financing commitment\" data-tweet=\"$DHCP - Walter Investment +52% as Barclays boosts financing commitment https://seekingalpha.com/news/3296488-walter-investmentplus-52-barclays-boosts-financing-commitment?source=tweet\" data-url=\"https://seekingalpha.com/news/3296488-walter-investmentplus-52-barclays-boosts-financing-commitment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296485\" data-ts=\"1505859563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORIG\" target=\"_blank\">ORIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296485-ocean-rig-to-effect-1-forminus-9200-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocean RIG to effect 1-for-9,200 reverse split</a></h4><ul>     <li>Ocean Rig UDW (NASDAQ:<a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a>)&nbsp;<font color='red'>-23.6%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16945510-ocean-rig-udw-inc-announces-reverse-stock-split\" target=\"_blank\">1-for-9,200 reverse stock split</a>, effective after the close of trading on Sept. 21.</li>     <li>The move will reduce the number of issued and outstanding common shares to ~8,976 shares from 82,586,851 currently.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296485\" data-linked=\"Ocean RIG to effect 1-for-9,200 reverse split\" data-tweet=\"$ORIG - Ocean RIG to effect 1-for-9,200 reverse split https://seekingalpha.com/news/3296485-ocean-rig-to-effect-1-forminus-9200-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3296485-ocean-rig-to-effect-1-forminus-9200-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296477\" data-ts=\"1505856983\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296477-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a> <font color='green'>+10.9%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+2.0%</font>. <a href='https://seekingalpha.com/symbol/CIG' title='Companhia Energtica de Minas Gerais - CEMIG'>CIG</a> <font color='green'>+1.6%</font>. <a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='green'>+1.3%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+1.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-12.0%</font>. <a href='https://seekingalpha.com/symbol/IOVA' title='Iovance Biotherapeutics, Inc.'>IOVA</a> <font color='red'>-6.4%</font>. <a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a> <font color='red'>-3.2%</font>. <a href='https://seekingalpha.com/symbol/WSM' title='Williams-Sonoma Inc.'>WSM</a> <font color='red'>-2.3%</font>. <a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color='red'>-2.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296477\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$GEMP $PULM $CIG - After Hours Gainers / Losers https://seekingalpha.com/news/3296477-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3296477-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296443\" data-ts=\"1505853632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296443-bed-bath-beyond-resumesminus-15-after-q2-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bed Bath &amp; Beyond resumes -15% after Q2 disappoints</a></h4><ul>   <li>Bed Bath &amp; Beyond (<a href=\"http://seekingalpha.com/symbol/BBBY\" target=\"_blank\">BBBY</a> <font color='red'>-1%</font>) was up 1.6% after hours, but came off a halt <font color='red'>down 15.1%</font> following <a href=\"https://seekingalpha.com/news/3296428-bed-bath-and-beyond-eps-0_67\" target=\"_blank\">Q2 earnings</a>, where it missed expectations due to hurricane and restructuring issues.</li>    <li>Net sales fell 1.7% and comparable sales fell 2.6%.</li>    <li>EPS was $0.67 vs. an expected $0.95, and included impacts of some $0.08/share in restructuring charges and $0.02/share in costs tied to Hurricane Harvey in the Gulf Coast, as well sa a new share-based payment accounting standard of approximately $.01 per diluted share, compared with $1.11 per diluted share a year ago.</li>    <li>It's now expecting EPS for the full year to be $3.00 (well below an expected $4.00) -- about 20% of that in fiscal Q3 and 80% in Q4.</li>    <li>The company will discuss \"undertaking a number of transformational initiatives\" in its <a href=\"http://edge.media-server.com/m/p/oqsvx37f/lan/en\" target=\"_blank\">conference call</a>, coming at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16945460-bed-bath-and-beyond-inc-reports-results-fiscal-2017-second-quarter\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296443\" data-linked=\"Bed Bath &amp; Beyond resumes -15% after Q2 disappoints\" data-tweet=\"$BBBY - Bed Bath &amp; Beyond resumes -15% after Q2 disappoints https://seekingalpha.com/news/3296443-bed-bath-beyond-resumesminus-15-after-q2-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3296443-bed-bath-beyond-resumesminus-15-after-q2-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296441\" data-ts=\"1505853567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296441-adobe-systems-beats-q3-guidance-estimates-shares-down-2_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adobe Systems beats Q3, guidance estimates; shares down 2.5%</a></h4><ul><li>        Adobe Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) shares are&nbsp;<font color='red'>down 2.49%</font>&nbsp;aftermarket despite Q3 revenue and EPS beats. The Q4 guidance matches revenue consensus at $1.95B and the expected $1.15 EPS beat consensus by five cents. &nbsp;</li><li>        Digital Media segment revenue was $1.27B with Annualized Recurring Revenue &#40;ARR&#41; at $4.87B. Adobe expects the segment to report a 25% revenue growth in Q4 on the prior year&rsquo;s quarter with net new ARR of $330M.</li><li>               Adobe Experience Cloud revenue was up 26% to $508M. Adobe expects the segment to report 17% growth in Q4.&nbsp;</li><li>               Division revenue: Subscription, $1.57B (+34% Y/Y); Product, $158.96M (-12%); Services and support, $111.78M (-2%).&nbsp;&nbsp;</li><li>               Operating expenses totaled $1B with $315.6M on R&amp;D, $550.1M on sales and marketing, and $147.4M on G&amp;A.&nbsp;</li><li>               Cash flow from operations totaled $704M. Deferred revenue was up nearly 10% on the year to $2.2B, driven by the Subscription growth. Adobe ended the quarter with $1.8B in cash and equivalents.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16945407-adobe-reports-record-revenue\" target=\"_blank\">Press release</a> / <a href=\"http://wwwimages.adobe.com/content/dam/acom/en/investor-relations/pdfs/91907102/4A23iMf9fEl1.pdf\" target=\"_blank\">Q4 guidance</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296413-adobe-systems-beats-0_09-beats-revenue\" target=\"_blank\">Adobe Systems beats by $0.09, beats on revenue</a> (Sept. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296441\" data-linked=\"Adobe Systems beats Q3, guidance estimates; shares down 2.5%\" data-tweet=\"$ADBE - Adobe Systems beats Q3, guidance estimates; shares down 2.5% https://seekingalpha.com/news/3296441-adobe-systems-beats-q3-guidance-estimates-shares-down-2_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3296441-adobe-systems-beats-q3-guidance-estimates-shares-down-2_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296438\" data-ts=\"1505853401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296438-fedexminus-2-earnings-underwhelm-full-year-guidance-lags-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx -2% as earnings underwhelm, full-year guidance lags consensus</a></h4><ul>     <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) <font color='red'>-2%</font>&nbsp;AH after reporting <a href=\"https://seekingalpha.com/news/3296425-fedex-eps-2_51\" target=\"_blank\">FQ1 earnings</a> of $2.51 per diluted share vs. $2.82 a year ago, reflecting the negative impact of the June 27 cyberattack affecting its TNT Express ($0.79/share) delivery unit and Hurricane Harvey ($0.02/share).</li>     <li>FDX issues downside guidance for FY 2018, seeing EPS of $12.00-$12.80 vs. $13.38 analyst consensus estimate, citing estimated full-year impacts of the TNT Express cyberattack, while reaffirming full-year capex guidance of $5.9B.</li>     <li>FDX also reaffirms its commitment to improve operating income at the FedEx Express segment by $1.2B-$1.5B by FY 2020 vs. 2017.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296438\" data-linked=\"FedEx -2% as earnings underwhelm, full-year guidance lags consensus\" data-tweet=\"$FDX - FedEx -2% as earnings underwhelm, full-year guidance lags consensus https://seekingalpha.com/news/3296438-fedexminus-2-earnings-underwhelm-full-year-guidance-lags-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3296438-fedexminus-2-earnings-underwhelm-full-year-guidance-lags-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296436\" data-ts=\"1505853253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOOL\" target=\"_blank\">KOOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296436-cesca-fiscal-2017-top-line-up-22-shares-ahead-6-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cesca fiscal 2017 top line up 22%; shares ahead 6% after hours</a></h4><ul><li>Cesca Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KOOL' title='Cesca Therapeutics Inc'>KOOL</a>) <a href=\"https://seekingalpha.com/pr/16945420-cesca-therapeutics-announces-fiscal-year-2017-financial-operating-results-provides-corporate\" target=\"_blank\">fiscal 2017 revenues</a> were $14.5M (+21.8%) while net loss widened to ($29.1M) (-56.5%).</li><li>Cash consumption increased 25% to $7.2M.</li><li>In fiscal Q4, acquired cell processing systems of SynGen, enhancing CAR T cell manufacturing capabilities.</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296436\" data-linked=\"Cesca fiscal 2017 top line up 22%; shares ahead 6% after hours\" data-tweet=\"$KOOL $THMO - Cesca fiscal 2017 top line up 22%; shares ahead 6% after hours https://seekingalpha.com/news/3296436-cesca-fiscal-2017-top-line-up-22-shares-ahead-6-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3296436-cesca-fiscal-2017-top-line-up-22-shares-ahead-6-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296432\" data-ts=\"1505852722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEMP\" target=\"_blank\">GEMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296432-gemphire-to-advance-gemcabene-phase-3-shares-ahead-13-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gemphire to advance gemcabene into Phase 3; shares ahead 13% after hours</a></h4><ul><li>Thinly traded micro cap Gemphire Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GEMP' title='Gemphire Therapeutics'>GEMP</a>) is up&nbsp;<font color='green'>13%</font>&nbsp;after hours on light volume in response to its <a href=\"https://seekingalpha.com/pr/16945394-gemphire-announces-plans-advance-gemcabene-phase-3-clinical-development\" target=\"_blank\">announcement </a>that it plans to advance high cholesterol fighter gemcabene into Phase 3 development in 2018.</li><li>The company plans to meet with U.S. and European regulators in Q1 to clarify the design of the Phase 3 programs.</li><li>Orphan Drug-tagged gemcabene is a once-daily orally available medication for patients unable to achieve normal levels of LDL-C or triglycerides with currently available therapies. It&nbsp;has a dual&nbsp;<a href=\"http://www.gemphire.com/products-and-trials.php#a-differentiated-product-profile\" target=\"_blank\">mechanism of action</a>&nbsp;that blocks the production of hepatic triglyceride and cholesterol synthesis and enhances the clearance of VLDL (very low density lipoprotein). Specifically, it inhibits a liver protein called apolipoprotein C-III and may inhibit a liver enzyme called acetyl-CoA carboxylase.&nbsp;Gemphire licensed it from Pfizer in April 2011.</li><li>Management will host a conference call at 4:30 pm ET today to discuss its plans.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3252486-gemphires-gemcabene-shows-cardiometabolic-benefit-mid-stage-study-obese-patients-shares-2\" target=\"_blank\">Gemphire's gemcabene shows cardiometabolic benefit in mid-stage study in obese patients; shares up 2%</a> (March 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296432\" data-linked=\"Gemphire to advance gemcabene into Phase 3; shares ahead 13% after hours\" data-tweet=\"$GEMP - Gemphire to advance gemcabene into Phase 3; shares ahead 13% after hours https://seekingalpha.com/news/3296432-gemphire-to-advance-gemcabene-phase-3-shares-ahead-13-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3296432-gemphire-to-advance-gemcabene-phase-3-shares-ahead-13-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296416\" data-ts=\"1505851698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGR\" target=\"_blank\">RGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296416-gun-stocks-gain-on-report-trump-set-to-ease-export-rules-for-u-s-guns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gun stocks gain on report Trump set to ease export rules for U.S. guns</a></h4><ul>     <li>Shares of U.S. gun makers surged into the close after a Reuters report that the Trump administration was preparing to <a href=\"https://www.reuters.com/article/us-usa-trump-weapons-exclusive/exclusive-trump-administration-prepares-to-ease-export-rules-for-u-s-guns-idUSKCN1BU2N8\" target=\"_blank\">make it easier for the companies to sell small arms to foreigners</a>: <a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company Inc.'>RGR</a> <font color='green'>+13.7%</font>, <a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='green'>+10.1</font>%, <a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a> <font color='green'>+3.1%</font>.</li>     <li>Aides to Pres. Trump are completing a plan to shift oversight of international non-military firearms sales from the security-focused State Department to the  trade-focused Commerce Department, and a draft of the new rules could be set to the White House budget office for review within days, according to the report.</li><li>The changes can be implemented without congressional approval and could  be made public this fall, with implementation coming as early as H1 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296416\" data-linked=\"Gun stocks gain on report Trump set to ease export rules for U.S. guns\" data-tweet=\"$RGR $RGR $AOBC - Gun stocks gain on report Trump set to ease export rules for U.S. guns https://seekingalpha.com/news/3296416-gun-stocks-gain-on-report-trump-set-to-ease-export-rules-for-u-s-guns?source=tweet\" data-url=\"https://seekingalpha.com/news/3296416-gun-stocks-gain-on-report-trump-set-to-ease-export-rules-for-u-s-guns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296407\" data-ts=\"1505851068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296407-sibanye-goldminus-9-on-450m-convertible-bond-issue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sibanye Gold -9% on $450M convertible bond issue</a></h4><ul>     <li>Sibanye Gold (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-9%</font>) sinks after launching an offering of <a href=\"http://www.barrons.com/articles/sibanye-gold-stock-sinks-5-on-new-convertible-bond-1505849330\" target=\"_blank\">$450M in senior unsecured convertible bonds</a>, diluting existing stockholders.</li>     <li>The 2023 bonds were expected to carry a coupon between 1.625% and 2.375%.</li>     <li>SBGL says the proceeds will be used to refinance a loan that was used partially to fund last year's $2.2B acquisition of Stillwater Mining.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296407\" data-linked=\"Sibanye Gold -9% on $450M convertible bond issue\" data-tweet=\"$SBGL - Sibanye Gold -9% on $450M convertible bond issue https://seekingalpha.com/news/3296407-sibanye-goldminus-9-on-450m-convertible-bond-issue?source=tweet\" data-url=\"https://seekingalpha.com/news/3296407-sibanye-goldminus-9-on-450m-convertible-bond-issue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296405\" data-ts=\"1505850985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTG\" target=\"_blank\">PSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296405-summit-redstone-pure-storage-approaching-potential-buyers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Redstone: Pure Storage approaching potential buyers</a></h4><ul><li>        Pure Storage (NYSE:<a href='https://seekingalpha.com/symbol/PSTG' title='Pure Storage'>PSTG</a>) has approached Cisco, IBM, and HP about a potential sale, according to Summit Redstone.</li><li>               <a href=\"http://www.barrons.com/articles/cisco-will-acquire-netapp-pure-is-shopping-itself-says-summit-redstone-1505846112\" target=\"_blank\">Barron&rsquo;s</a> has the note from analyst Srini Nandury, which also mentions that Cisco is more likely to acquire NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>)&nbsp;&ldquo;given that NetApp will be immediately accretive ($5.8B revenue for 2018).&rdquo;&nbsp;</li><li>               Nandury&rsquo;s writes that Pure Storage knows new customer acquisition is &ldquo;slow and tedious, given that the power of incumbency in storage is hard to dislodge.&rdquo; The analyst thinks Pure Storage has growth potential in its Flash Blade product.&nbsp;</li><li>                  Pure Storage shares are&nbsp;<font color='green'>up 0.27%</font>.    </li><li>                  NetApp shares are&nbsp;<font color='green'>up 2.84%</font>.&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3291842-pure-storage-names-new-ceo-shares-12_7-percent\" target=\"_blank\">Pure Storage names new CEO; shares up 12.7%</a> (Aug. 25)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296329-ubs-upgrades-netapp-increases-price-target\" target=\"_blank\">UBS upgrades NetApp, increases price target</a> (Sept. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296405\" data-linked=\"Summit Redstone: Pure Storage approaching potential buyers\" data-tweet=\"$PSTG $PSTG $NTAP - Summit Redstone: Pure Storage approaching potential buyers https://seekingalpha.com/news/3296405-summit-redstone-pure-storage-approaching-potential-buyers?source=tweet\" data-url=\"https://seekingalpha.com/news/3296405-summit-redstone-pure-storage-approaching-potential-buyers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296398\" data-ts=\"1505849536\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROSG-OLD\" target=\"_blank\">ROSG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296398-rosetta-nabs-u-s-patent-covering-microrna-in-gastric-cancer-shares-ahead-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosetta nabs U.S. patent covering microRNA in gastric cancer; shares ahead 12%</a></h4><ul><li>Thinly traded nano cap Rosetta Genomics (<a href='https://seekingalpha.com/symbol/ROSG-OLD' title='Rosetta Genomics Ltd.'>ROSG-OLD</a> <font color='green'>+12.1%</font>) heads north on more than a 21x surge in volume in apparent response a new composition of matter and method of use <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=/netahtml/PTO/srchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=9765334.PN.&amp;OS=PN/9765334&amp;RS=PN/9765334\" target=\"_blank\">patent </a>(U.S. No. 9,765,334) covering microRNA molecules associated with the prognosis of gastric cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296398\" data-linked=\"Rosetta nabs U.S. patent covering microRNA in gastric cancer; shares ahead 12%\" data-tweet=\"$ROSG-OLD - Rosetta nabs U.S. patent covering microRNA in gastric cancer; shares ahead 12% https://seekingalpha.com/news/3296398-rosetta-nabs-u-s-patent-covering-microrna-in-gastric-cancer-shares-ahead-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3296398-rosetta-nabs-u-s-patent-covering-microrna-in-gastric-cancer-shares-ahead-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296399\" data-ts=\"1505849488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIA\" target=\"_blank\">ACIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296399-acacia-communicationsplus-3_8-after-mkm-starts-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acacia Communications +3.8% after MKM starts at Buy</a></h4><ul>   <li>Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) is <font color='green'>up 3.8%</font> today and has reached its highest point since April after an initiation by MKM Partners starts the company at Buy.</li>    <li>It's the only optical component stock that MKM would recommend to \"long-term investors with a 3+ year time horizon,\" according to analyst Michael Genovese.</li>    <li>That's due in part to advantages including high quality and quick introductions of its digital signal processor chips, he says.</li>    <li>He has a price target of $64 on <a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>, implying 34.5% upside from today's higher price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296399\" data-linked=\"Acacia Communications +3.8% after MKM starts at Buy\" data-tweet=\"$ACIA - Acacia Communications +3.8% after MKM starts at Buy https://seekingalpha.com/news/3296399-acacia-communicationsplus-3_8-after-mkm-starts-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3296399-acacia-communicationsplus-3_8-after-mkm-starts-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296396\" data-ts=\"1505848654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVI\" target=\"_blank\">CVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296396-reuters-icahns-cvr-energy-starts-unwinding-biofuels-bet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Icahn&#39;s CVR Energy starts unwinding biofuels bet</a></h4><ul>     <li>CVR&nbsp;Energy (<a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='green'>+2.9%</font>) has begun <a href=\"http://www.reuters.com/article/us-cvr-energy-biofuels/icahns-oil-refiner-cvr-starts-unwinding-biofuels-bet-idUSKCN1BU2H3?il=0\" target=\"_blank\">buying biofuel credits for the first time in months</a>, a sign that the Carl Icahn-led company is starting to unwind a massive short position in the biofuels market, Reuters reports.</li>     <li>The company has purchased millions of the RINs since late August, according to the report, and appears to have spread the purchases among different brokers, which would help keep it from attracting sellers looking to bid up the price.</li>     <li>CVR delayed buying credits for much of the past year in hopes prices would come down, building up a company-record $280M outstanding obligation, amid hopes the Trump administration would revamp U.S. biofuels policy in a way that shifts the blending burden off refiners such as CVR further down the supply chain to terminals.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296396\" data-linked=\"Reuters: Icahn&#39;s CVR Energy starts unwinding biofuels bet\" data-tweet=\"$CVI - Reuters: Icahn&#39;s CVR Energy starts unwinding biofuels bet https://seekingalpha.com/news/3296396-reuters-icahns-cvr-energy-starts-unwinding-biofuels-bet?source=tweet\" data-url=\"https://seekingalpha.com/news/3296396-reuters-icahns-cvr-energy-starts-unwinding-biofuels-bet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296394\" data-ts=\"1505848225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296394-pulmatrix-ceo-bullish-on-pipeline-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix CEO bullish on pipeline; shares ahead 9%</a></h4><ul><li>Thinly traded nano cap Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+8.5%</font>) jumps on more than triple normal volume in apparent response to <a href=\"http://ih.advfn.com/p.php?pid=nmona&amp;article=75680950&amp;adw=1126416\" target=\"_blank\">comments </a>made earlier today by CEO Dr. Robert Clarke during an <a href=\"https://upticknewswire.com/interview-ceo-dr-robert-clarke-of-pulmatrix-inc-nasdaq-pulm\" target=\"_blank\">interview </a>on the Uptick Network.</li><li>He discussed the company's partnership with Vecturato to develop COPD candidate PUR0200, explaining that Vecturato and its partners will be responsible for all future development costs in the U.S. The deal includes a technology transfer fee and mid-teen percent revenue share.</li><li>He also highlighted PUR1800, the lead candidate from the RespiVert deal, another candidate for COPD, calling it a potential blockbuster.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296394\" data-linked=\"Pulmatrix CEO bullish on pipeline; shares ahead 9%\" data-tweet=\"$PULM - Pulmatrix CEO bullish on pipeline; shares ahead 9% https://seekingalpha.com/news/3296394-pulmatrix-ceo-bullish-on-pipeline-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3296394-pulmatrix-ceo-bullish-on-pipeline-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296393\" data-ts=\"1505848165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTDOY\" target=\"_blank\">NTDOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296393-nintendo-tags-nine-year-high-amid-tencent-deal-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nintendo tags nine-year high amid Tencent deal, upgrade</a></h4><ul>   <li>Nintendo (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a>) is <font color='green'>up 5.3%</font> in U.S. trading after earning an upgrade to Outperform from Credit Suisse, which sees <a href=\"http://www.investors.com/news/technology/click/nintendo-stock-jumps-on-upgrade-switchs-sales-prospects/\" target=\"_blank\">much stronger sales of its Switch console</a> ahead.</li>    <li>\"We had previously expected the Switch to sell like a traditional console, but now expect it to sell more like a handheld,\" says analyst Keiichi Yoneshima, who's bumping a forecast of 70M unit sales through 2022 up to 130M units.</li>    <li>Meanwhile, a deal for a Switch version of one of China's most popular games -- Tencent's (<a href=\"http://seekingalpha.com/symbol/TCEHY\" target=\"_blank\">TCEHY</a> <font color='red'>-1.1%</font>) <i>Honor of Kings</i> -- could set the path for a potentially <a href=\"https://www.wsj.com/articles/nintendo-deal-with-tencent-paves-way-for-china-push-1505825294\" target=\"_blank\">lucrative entry into China</a>.</li>    <li>The Switch isn't currently sold in China, but that prospect seems closer now with the Tencent deal. <i>Honor of Kings</i> is called <i>Arena of Valor</i> in Europe and will be launched under that name in the U.S. later this year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296393\" data-linked=\"Nintendo tags nine-year high amid Tencent deal, upgrade\" data-tweet=\"$NTDOY $NTDOY $TCEHY - Nintendo tags nine-year high amid Tencent deal, upgrade https://seekingalpha.com/news/3296393-nintendo-tags-nine-year-high-amid-tencent-deal-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3296393-nintendo-tags-nine-year-high-amid-tencent-deal-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296390\" data-ts=\"1505847422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296390-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+66%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+29%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296390\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$HMNY $VERI $OPNT - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3296390-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296390-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296388\" data-ts=\"1505847043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCEL\" target=\"_blank\">FCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296388-fuelcell-energyplus-4-cowen-lauds-carbon-capture-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FuelCell Energy +4% as Cowen lauds carbon capture technology</a></h4><ul><li>FuelCell Energy (<a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='green'>+4.1%</font>) moves sharply higher after Cowen analyst Jeffrey Osborne says Exxon Mobil's (<a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a> <font color='green'>+0.1%</font>) foray into carbon capture and storage technology with the company is \"<a href=\"https://www.bloomberg.com/news/articles/2017-09-19/exxon-mobil-s-futuristic-fuelcell-carbon-capture-just-might-work\" target=\"_blank\">making progress</a>.\"</li><li>The technology, which has moved from the lab to a commercial test at a power plant in Alabama, <a href=\"https://cowen.bluematrix.com/sellside/EmailDocViewer?encrypt=b669d894-b157-45b4-b8dc-8077d124f580&amp;co=Cowen&amp;mime=PDF&amp;id=replaceme@bluematrix.com\" target=\"_blank\">could be licensed globally</a> to help countries reach greenhouse gas reduction targets, Cowen says, viewing \"a successful launch of this technology, albeit in the outer years, as material to the outlook for natural gas demand.\"</li><li>Capturing 90% of the emissions at just 1% of U.S. coal  plants would require 2,160 MW of fuel cells, equal to ~$6.5 B in sales and $9.7B in service revenue, Osborne estimates; FCEL's total sales in FY 2016 were just $108M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296388\" data-linked=\"FuelCell Energy +4% as Cowen lauds carbon capture technology\" data-tweet=\"$FCEL $FCEL $XOM - FuelCell Energy +4% as Cowen lauds carbon capture technology https://seekingalpha.com/news/3296388-fuelcell-energyplus-4-cowen-lauds-carbon-capture-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3296388-fuelcell-energyplus-4-cowen-lauds-carbon-capture-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296383\" data-ts=\"1505846435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMT\" target=\"_blank\">AMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296383-wells-fargo-many-tower-firm-catalysts-even-sprint-t-mobile-merge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo: Many tower-firm catalysts even if Sprint, T-Mobile merge</a></h4><ul>   <li>Even with Sprint and T-Mobile reported (again) to be in <a href=\"https://seekingalpha.com/news/3296308-sprint-plus-4_2-percent-t-mobile-plus-1_6-percent-report-active-merger-talks\" target=\"_blank\">merger talks</a>, a deal between them wouldn't \"kill other tower catalysts,\" Wells Fargo says in an endorsement of communications tower stocks that have declined following news of the discussions.</li>    <li>Analyst Jennifer Fritzsche has an Outperform rating on American Tower (NYSE:<a href='https://seekingalpha.com/symbol/AMT' title='American Tower Corporation'>AMT</a>) and Crown Castle International (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a>). <a href='https://seekingalpha.com/symbol/AMT' title='American Tower Corporation'>AMT</a>, down as much as 4.1% previously, is <font color='red'>down 2.5%</font> now. <a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a> has recovered to a <font color='red'>2.2% decline</font>.</li>    <li>She rates SBA Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/SBAC' title='SBA Communications Corporation'>SBAC</a>) Market Perform; that stock is <font color='red'>down 2.7%</font> today.</li>    <li>The two carriers would comment \"loudly\" about network/backhaul savings if they merged, which would have varying effects depending on the tower firms' exposure to the two: <a href='https://seekingalpha.com/symbol/AMT' title='American Tower Corporation'>AMT</a> 4% of revenue with 5 years left on a contract; <a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a> 8% of revenue with 5-6 years remaining; <a href='https://seekingalpha.com/symbol/SBAC' title='SBA Communications Corporation'>SBAC</a> 5% of revenue with 3-5 years remaining.</li>    <li>But the tower firms have much to look forward to ahead alongside growing wireless demand, spectrum deployment and AT&amp;T's FirstNet buildout (h/t Bloomberg).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296383\" data-linked=\"Wells Fargo: Many tower-firm catalysts even if Sprint, T-Mobile merge\" data-tweet=\"$AMT $AMT $CCI - Wells Fargo: Many tower-firm catalysts even if Sprint, T-Mobile merge https://seekingalpha.com/news/3296383-wells-fargo-many-tower-firm-catalysts-even-sprint-t-mobile-merge?source=tweet\" data-url=\"https://seekingalpha.com/news/3296383-wells-fargo-many-tower-firm-catalysts-even-sprint-t-mobile-merge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296379\" data-ts=\"1505845126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296379-ge-slides-again-j-p-morgan-analyst-doubles-down-on-bearish-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE slides again as J.P. Morgan analyst doubles down on bearish view</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-1.6%</font>) tumbles to within ~$0.50 of its 52-week low as J.P. Morgan analyst Stephen Tusa <a href=\"http://www.marketwatch.com/story/general-electrics-stock-falls-after-jp-morgan-analyst-reiterates-bearish-view-2017-09-19\" target=\"_blank\">reiterates his bearish view</a>, suggesting that just because the stock keeps getting cheaper does not make it more attractive.</li>     <li>Tusa says as the stock's weakness continues, investors and analysts appear to try to create a bullish narrative based mostly on how far the stock has fallen, but analysts have been careful not to raise their ratings, which he believes \"defines sentiment on the stock, which is somewhere between somewhat negative, and what we would characterize as 'chicken bullish'... essentially a denial that fundamentals could be this bad, and there is nothing that simple cost saves can't take care of, something that was not obvious to the previous 15 years of management.\"</li>     <li>In his <a href=\"https://www.cnbc.com/2017/09/07/jpmorgan-says-ges-fundamentals-are-worse-than-we-think.html\" target=\"_blank\">earlier bearish note</a>, Tusa looked at GE&nbsp;and saw \"a core operating performance that is below plan, and, currently, a consensus expectations curve that we think remains too high, [free cash flow] that is the weakest in the sector, and, with that  backdrop, a valuation that is expensive, with limited incremental catalysts to change the narrative.\"</li>     <li>JPM rates GE at Underweight with a $22 price target; shares, which closed at a two-year low $23.72 on Sept. 11, has fallen 24% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296379\" data-linked=\"GE slides again as J.P. Morgan analyst doubles down on bearish view\" data-tweet=\"$GE - GE slides again as J.P. Morgan analyst doubles down on bearish view https://seekingalpha.com/news/3296379-ge-slides-again-j-p-morgan-analyst-doubles-down-on-bearish-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3296379-ge-slides-again-j-p-morgan-analyst-doubles-down-on-bearish-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>84&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296377\" data-ts=\"1505844607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPG\" target=\"_blank\">SPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296377-best-buys-tumble-pushes-mall-owners-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy&#39;s tumble pushes mall owners lower</a></h4><ul><li>Best Buy slumped as much as 10% this session, and is currently&nbsp;<font color='red'>down 7%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3296326-long-term-forecast-best-buy-disappoints\" target=\"_blank\">issuing disappointing guidance</a> ahead as part of its investor day presentation.</li><li>The company's landlords - Simon Property (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='red'>-1%</font>), GGP (GGP <font color='red'>-1%</font>), Weingarten Realty (<a href='https://seekingalpha.com/symbol/WRI' title='Weingarten Realty Investors'>WRI</a> <font color='red'>-1.3%</font>), and Macerich (<a href='https://seekingalpha.com/symbol/MAC' title='Macerich Co.'>MAC</a> <font color='red'>-1.7%</font>) among them - are under pressure today as well.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296377\" data-linked=\"Best Buy&#39;s tumble pushes mall owners lower\" data-tweet=\"$SPG $SPG $BPR - Best Buy&#39;s tumble pushes mall owners lower https://seekingalpha.com/news/3296377-best-buys-tumble-pushes-mall-owners-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3296377-best-buys-tumble-pushes-mall-owners-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296375\" data-ts=\"1505844063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296375-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ESES' title='Eco-Stim Energy Solutions, Inc.'>ESES</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GDP' title='Goodrich Petroleum Corp.'>GDP</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc'>BRN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296375\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$JONE $SNES $VHI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3296375-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296375-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296374\" data-ts=\"1505843840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOSYY\" target=\"_blank\">TOSYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296374-reuters-toshiba-back-to-favoring-wdc-in-chip-unit-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Toshiba back to favoring WDC in chip unit sale</a></h4><ul>   <li>In a surprise move, Toshiba (<a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a> <font color='red'>-1.7%</font>) has drifted back to favoring selling its semiconductor unit to a <a href=\"https://www.reuters.com/article/us-toshiba-sale-exclusive/exclusive-toshiba-flips-back-to-favoring-western-digital-group-for-chip-unit-sale-sources-idUSKCN1BU2EY?feedType=RSS&amp;feedName=businessNews\" target=\"_blank\">group backed by Western Digital</a> (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>), Reuters reports.</li>    <li><a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>, previously negative on the day, has spiked to a <font color='green'>1.4% gain</font>.</li>    <li>Sources told the news service that Western Digital (already a JV partner with Toshiba) is making key concessions to promise it wouldn't attempt to control the business in the future.</li>    <li>That would change the situation from what appeared to be a favored deal for the consortium led by Bain Capital and SK Hynix.</li>    <li>Toshiba's board is to meet Wednesday, but with this potential game-changing bid status fresh in the news, so a decision may not be imminent.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296374\" data-linked=\"Reuters: Toshiba back to favoring WDC in chip unit sale\" data-tweet=\"$TOSYY $TOSYY $WDC - Reuters: Toshiba back to favoring WDC in chip unit sale https://seekingalpha.com/news/3296374-reuters-toshiba-back-to-favoring-wdc-in-chip-unit-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3296374-reuters-toshiba-back-to-favoring-wdc-in-chip-unit-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296497\" data-ts=\"1505843725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTS\" target=\"_blank\">WTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296497-watts-water-tech-started-buy-curtiss-wright-hold-stifel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Watts Water Tech started as a Buy, Curtiss-Wright a Hold at Stifel</a></h4><ul>     <li>Watts Water Technologies (<a href='https://seekingalpha.com/symbol/WTS' title='Watts Water Technologies, Inc.'>WTS</a> <font color='green'>+2.2%</font>) is initiated with a <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Starts+Watts+Waters+%28WTS%29+at+Buy/13305780.html\" target=\"_blank\">Buy rating</a> and $72 stock price target at Stifel, which believes WTS is in the early stages of an operational turnaround with significant opportunities on multiple fronts to improve both growth and profitability.</li>     <li>At the same time, Stifel says WTS has a long way to go to achieve acceptable operational performance, including improving the process control and capabilities out of its foundry to increase throughput, and improve material flow through while also reducing waste and increasing capacity.</li>     <li>However, the firm initiates Curtiss-Wright (<a href='https://seekingalpha.com/symbol/CW' title='Curtiss-Wright Corporation'>CW</a> <font color='red'>-0.7%</font>) with a <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Starts+Curtiss-Wright+%28CW%29+at+Hold/13305793.html\" target=\"_blank\">Hold rating</a> and $100 price target, expecting improving growth during the next several years driven by its nuclear  reactor coolant pump business and increased content on future generation nuclear submarines and aircraft carriers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296497\" data-linked=\"Watts Water Tech started as a Buy, Curtiss-Wright a Hold at Stifel\" data-tweet=\"$WTS $WTS $CW - Watts Water Tech started as a Buy, Curtiss-Wright a Hold at Stifel https://seekingalpha.com/news/3296497-watts-water-tech-started-buy-curtiss-wright-hold-stifel?source=tweet\" data-url=\"https://seekingalpha.com/news/3296497-watts-water-tech-started-buy-curtiss-wright-hold-stifel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296371\" data-ts=\"1505841956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PG\" target=\"_blank\">PG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296371-procter-gamble-goes-on-offensive-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Procter &amp; Gamble goes on the offensive again</a></h4><ul>     <li>Procter &amp; Gamble (<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='green'>+1.3%</font>) issues an updated investor presentation to highlight the transformation overseen by its board and management team.</li>     <li>\"The changes needed to accelerate growth are already being implemented.       We have strengthened and streamlined our portfolio, simplified our       structure and significantly enhanced P&amp;G&rsquo;s productivity,\" says CEO David Taylor.</li>     <li>The full P&amp;G&nbsp;presentation is available at <a href=\"http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvoteblue.pg.com%2Four-plan&amp;esheet=51686438&amp;newsitemid=20170919006418&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvoteblue.pg.com%2Four-plan&amp;index=1&amp;md5=a1817542a4f263e029e3f173142befb4\" target=\"_blank\">https://voteblue.pg.com/our-plan</a>.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3296300-procter-and-gambles-battle-nelson-peltz-ratchets\" target=\"_blank\">Procter &amp; Gamble's battle with Nelson Peltz ratchets up again</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3296371\" data-linked=\"Procter &amp; Gamble goes on the offensive again\" data-tweet=\"$PG - Procter &amp; Gamble goes on the offensive again https://seekingalpha.com/news/3296371-procter-gamble-goes-on-offensive-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3296371-procter-gamble-goes-on-offensive-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296363\" data-ts=\"1505840347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296363-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TREE' title='LendingTree, Inc.'>TREE</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296363\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$TREE $FANH - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3296363-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296363-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296360\" data-ts=\"1505839837\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296360-investors-assess-new-landscape-for-toys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors assess new landscape for toys</a></h4><ul> <li>Toy sellers will be closely watched heading into the holiday season as the bankruptcy of Toys \"R\" Us takes away a main testing ground of new products and concepts. Analysts <a href=\"http://www.npr.org/sections/thetwo-way/2017/09/19/551993537/ahead-of-the-holiday-season-toys-r-us-files-for-bankruptcy-protection\" target=\"_blank\">note</a> that Toys \"R\" Us was the largest toy chain standing after swallowing up FAO Schwarz and Kay Bee Toys, a distinction that now adds some uncertainty to the industry after the bankruptcy filing..</li> <li>Sector check on popularity:&nbsp;On TTPM.com's <a href=\"https://ttpm.com/most-popular/\" target=\"_blank\">list</a> of the 25 most viewed toys, Hasbro tops the list with 9 entries, while Spin Master was second with 3 products listed. Mattel and MGA Entertainment (private) both have two toy items on the list.</li>  <li>Sector check on shares prices:&nbsp;Mattel (<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='green'>+1.1%</font>) and Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='green'>+1.6%</font>) are higher in the U.S., while Spin Master (<a href='https://seekingalpha.com/symbol/SNMSF' title='SPIN MASTER CORP'>OTC:SNMSF</a>) is <font color='green'>down 1.82%</font> in Toronto. JAKKS Pacific (<a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a> <font color='red'>-1.8%</font>) trades just off its 52-week low. The bankruptcy of Toys \"R\" Us could have some incremental benefit for Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+0.3%</font>) and Wal-Mart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) heading into the holiday season if they can box out Amazon.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296197-toys-r-us-files-bankruptcy\" target=\"_blank\">Toys 'R' Us files for bankruptcy</a> (Sept. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296261-toy-stocks-react-toys-r-us-bankruptcy\" target=\"_blank\">Toy stocks react to Toys \"R\" Us bankruptcy</a> (Sept. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296360\" data-linked=\"Investors assess new landscape for toys\" data-tweet=\"$MAT $MAT $HAS - Investors assess new landscape for toys https://seekingalpha.com/news/3296360-investors-assess-new-landscape-for-toys?source=tweet\" data-url=\"https://seekingalpha.com/news/3296360-investors-assess-new-landscape-for-toys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296358\" data-ts=\"1505839650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPSEY\" target=\"_blank\">IPSEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296358-ipsens-xermelo-okd-in-europe-for-carcinoid-syndrome-diarrhea-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ipsen&#39;s Xermelo OK&#39;d in Europe for carcinoid syndrome diarrhea; shares ahead 5%</a></h4><ul><li>The European Commission <a href=\"https://seekingalpha.com/pr/16945182-ipsen-receives-approval-european-commission-xermelo-telotristat-ethyl-treatment-carcinoid\" target=\"_blank\">approves </a>Ipsen's (<a href='https://seekingalpha.com/symbol/IPSEY' title='Ipsen S.A. ADR'>OTCPK:IPSEY</a> <font color='green'>+5%</font>) Xermelo (telotristat ethyl), in combination with a somatostatin analogue &#40;SSA&#41;, for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled with SSA therapy.</li><li><a href=\"http://www.webmd.com/cancer/carcinoid-syndrome#1\" target=\"_blank\">Carcinoid syndrome</a> is a group of symptoms similar to asthma, irritable bowel syndrome and menopause that occur after carcinoid tumors release certain chemicals into the bloodstream.</li><li>Telotristat ethyl inhibits an enzyme called typtophan hydroxylase which reduces the production of serotonin within neuroendocrine tumors.</li><li>Lexicon Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a> <font color='red'>-1.6%</font>) has commercialization rights in the U.S. The FDA approved Xermelo for the indication in February.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296358\" data-linked=\"Ipsen&#39;s Xermelo OK&#39;d in Europe for carcinoid syndrome diarrhea; shares ahead 5%\" data-tweet=\"$IPSEY $IPSEY $LXRX - Ipsen&#39;s Xermelo OK&#39;d in Europe for carcinoid syndrome diarrhea; shares ahead 5% https://seekingalpha.com/news/3296358-ipsens-xermelo-okd-in-europe-for-carcinoid-syndrome-diarrhea-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3296358-ipsens-xermelo-okd-in-europe-for-carcinoid-syndrome-diarrhea-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296357\" data-ts=\"1505839228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296357-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+53%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='green'>+34%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/ACTG' title='Acacia Research Corporation'>ACTG</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NVCN' title='Neovasc Inc.'>NVCN</a> <font color='green'>+12%</font>. EBIO <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='red'>-39%</font>. <a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/BRN' title='Barnwell Industries, Inc'>BRN</a> <font color='red'>-11%</font>. LTEA <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296357\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CAPR $VERI $HMNY - Midday Gainers / Losers https://seekingalpha.com/news/3296357-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3296357-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296355\" data-ts=\"1505838528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEE\" target=\"_blank\">SEE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296355-sealed-air-sinks-to-52-week-low-barclays-says-shares-relatively-rich\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sealed Air sinks to 52-week low; Barclays says shares &quot;relatively rich&quot;</a></h4><ul>     <li>Sealed Air (<a href='https://seekingalpha.com/symbol/SEE' title='Sealed Air Corporation'>SEE</a> <font color='red'>-2.9%</font>) breaks down to a 52-week low, as Barclays resumes coverage of SEE with an <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Reinstates+Sealed+Air+%28SEE%29+at+Equalweight%2C+Current+Valuation+is+Relatively+Rich+at+11x+EVEBITDA/13306695.html\" target=\"_blank\">Equal Weight rating</a> and a $45 target price, saying its current valuation at 11x enterprise value/EBITDA is \"relatively rich.\"</li>     <li>Prior to suspending its rating in March, Barclays expected accelerating  organic growth in the underlying Food and Product Care businesses along with a value unlock related to the sale of Diversey by Bain; the firm says it was partially correct but unforeseen topline and input cost headwinds have developed since then, making 2017 another transition year similar to 2016.</li>     <li>Barclays believes SEE must now use the underwhelming Diversey sale for repurchases and debt paydown over the next two years to try to offset earnings dilution; also, growth in Food Care and Product Care has materialized but with offsetting trends outside North America along with some disappointing margin performance.</li>     <li>SunTrust recently noted that the news of CEO Jerome Peribere's <a href=\"https://seekingalpha.com/news/3294272-sealed-air-ceo-peribere-retire-succeeded-doheny\" target=\"_blank\">retirement</a> makes a <a href=\"http://thefly.com/thestreet/realmoney/index.php/SEE;BMSid2606565/SEE;BMS-Sealed-Air-unlikely-to-be-acquired-after-new-CEO-named--says-SunTrust\" target=\"_blank\">sale of the company unlikely</a> in the near-term, although the firm kept its Buy rating and $48 price target on the shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296355\" data-linked=\"Sealed Air sinks to 52-week low; Barclays says shares &quot;relatively rich&quot;\" data-tweet=\"$SEE - Sealed Air sinks to 52-week low; Barclays says shares &quot;relatively rich&quot; https://seekingalpha.com/news/3296355-sealed-air-sinks-to-52-week-low-barclays-says-shares-relatively-rich?source=tweet\" data-url=\"https://seekingalpha.com/news/3296355-sealed-air-sinks-to-52-week-low-barclays-says-shares-relatively-rich\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296354\" data-ts=\"1505838319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPIC\" target=\"_blank\">GPIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296354-casino-sector-catches-bids\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Casino sector catches some bids</a></h4><ul><li>Investors are placing bets in the casino sector as the outlook on U.S. discretionary spending improves a bit. Resort operators and suppliers are both drawing some industry.</li><li>Gaming Partners International (<a href='https://seekingalpha.com/symbol/GPIC' title='Gaming Partners International Corporation'>GPIC</a> <font color='green'>+2.2%</font>), Scientific Games (<a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corp'>SGMS</a> <font color='green'>+1.5%</font>), Dover Downs (<a href='https://seekingalpha.com/symbol/DDE' title='Dover Downs Gaming & Entertainment, Inc.'>DDE</a> <font color='green'>+4%</font>), Caesars Entertainment (<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment'>CZR</a> <font color='green'>+2.9%</font>), MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='green'>+2%</font>), Monarch Casino &amp; Resort (<a href='https://seekingalpha.com/symbol/MCRI' title='Monarch Casino & Resort, Inc.'>MCRI</a> <font color='green'>+2.2%</font>) and Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='green'>+2.2%</font>) are all higher on the day.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296354\" data-linked=\"Casino sector catches some bids\" data-tweet=\"$GPIC $GPIC $SGMS - Casino sector catches some bids https://seekingalpha.com/news/3296354-casino-sector-catches-bids?source=tweet\" data-url=\"https://seekingalpha.com/news/3296354-casino-sector-catches-bids\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296348\" data-ts=\"1505837097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296348-teva-teams-up-nuvelution-pharma-to-accelerate-development-of-austedo-for-tourette-syndrome\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva teams up with Nuvelution Pharma to accelerate development of Austedo for Tourette syndrome; shares up 1%</a></h4><ul><li>Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='green'>+0.7%</font>) inks an agreement with privately held Nuvelution Pharma aimed at accelerating development of <a href=\"https://austedo.com/\" target=\"_blank\">AUSTEDO</a> (deutetrabenazine) for the treatment of a movement disorder called <a href=\"https://www.tourette.org/about-tourette/overview/what-is-tourette/\" target=\"_blank\">Tourette syndrome</a>.</li><li>Under the terms of the agreement, Nuvelution will fund and manage clinical development while Teva will be responsible for the regulatory process and commercialization. Upon FDA approval, Teva will pay Nuvelution a pre-agreed return on its invested capital. A Phase 3 study should start in Q4.</li><li>AUSTEDO is currently approved in the U.S. for tardive dyskinesia and chorea associated with Huntington's disease.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296348\" data-linked=\"Teva teams up with Nuvelution Pharma to accelerate development of Austedo for Tourette syndrome; shares up 1%\" data-tweet=\"$TEVA - Teva teams up with Nuvelution Pharma to accelerate development of Austedo for Tourette syndrome; shares up 1% https://seekingalpha.com/news/3296348-teva-teams-up-nuvelution-pharma-to-accelerate-development-of-austedo-for-tourette-syndrome?source=tweet\" data-url=\"https://seekingalpha.com/news/3296348-teva-teams-up-nuvelution-pharma-to-accelerate-development-of-austedo-for-tourette-syndrome\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296347\" data-ts=\"1505837024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296347-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a> <font color='green'>+10%.</font></li><li><b>Losers:</b> LTEA <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/VGR' title='Vector Group Ltd.'>VGR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296347\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$CLXT $LBCC $VGR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3296347-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3296347-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296345\" data-ts=\"1505836288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REXX\" target=\"_blank\">REXX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296345-rex-energy-says-on-track-to-meet-q3-full-year-production-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rex Energy says on track to meet Q3, full-year production guidance</a></h4><ul>     <li>Rex Energy (<a href='https://seekingalpha.com/symbol/REXX' title='Rex Energy Corporation'>REXX</a> <font color='green'>+3.7%</font>) is on the rise following an <a href=\"https://seekingalpha.com/pr/16943995-correcting-replacing-rex-energy-provides-moraine-east-area-operations-update\" target=\"_blank\">update for its Moraine East Area operations</a>, which it says keeps it on target to meet quarterly and  full-year guidance after production snags hurt volumes in Q2.</li>     <li>Rex says it turned 12 wells to sales in western Pennsylvania during Q3, which ensures it will remain on target to meet its Q3 production guidance of 171M-181M cfe/day and its FY 207 exit rate production growth rate guidance of 15%-20% in the 180M-190M cfe/day forecast range.</li>     <li>Rex says the six-well Shields pad has produced at an average 30-day sales rate/well of 7.9M cfe/day., and the four-well Mackrell pad has produced average output of 8.4M cfe/day each.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296345\" data-linked=\"Rex Energy says on track to meet Q3, full-year production guidance\" data-tweet=\"$REXX - Rex Energy says on track to meet Q3, full-year production guidance https://seekingalpha.com/news/3296345-rex-energy-says-on-track-to-meet-q3-full-year-production-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3296345-rex-energy-says-on-track-to-meet-q3-full-year-production-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296335\" data-ts=\"1505834734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVHC\" target=\"_blank\">EVHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296335-envision-shakes-up-management-to-buy-back-250m-in-shares-investors-unmoved-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Envision shakes up management, to buy back $250M in shares; investors unmoved, shares down 7%</a></h4><ul><li>Envision Healthcare (<a href='https://seekingalpha.com/symbol/EVHC' title='Envision Healthcare Holdings'>EVHC</a> <font color='red'>-7.4%</font>) continues its slide on almost double normal volume. Selling has intensified since last week. Shares have lost over&nbsp;<font color='red'>13%</font>&nbsp;of their value on progressively higher turnover.</li><li>After the close yesterday, the company made two announcements, one a <a href=\"https://seekingalpha.com/pr/16943867-envision-healthcare-announces-organizational-changes-align-senior-leadership-structure\" target=\"_blank\">management shakeup</a> and the other a <a href=\"https://seekingalpha.com/pr/16943880-envision-healthcare-announces-250-million-stock-repurchase\" target=\"_blank\">share repurchase plan</a>.</li><li>With the aim of creating alignment with its physician-centric strategy, the company has appointed Karey Whitty as EVP and Chief Operating Officer effective October 2. He joins the firm from Corizon Health where he was CEO.</li><li>Other changes: Chief Accounting Officer Kevin Eastridge will succeed retiring Claire Gulmi as CFO with SVP, Financial Reporting Kenneth Zongor backfilling Mr. Eastridge as CAO.</li><li>COO of the Physician Services Group Brian Jackson will assume the role of President of Physician Services succeeding Robert Coward who will resign. All moves will be effective October 2.</li><li>The board has authorized the repurchase of $250M of common stock which represents ~4% of outstanding shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296335\" data-linked=\"Envision shakes up management, to buy back $250M in shares; investors unmoved, shares down 7%\" data-tweet=\"$EVHC - Envision shakes up management, to buy back $250M in shares; investors unmoved, shares down 7% https://seekingalpha.com/news/3296335-envision-shakes-up-management-to-buy-back-250m-in-shares-investors-unmoved-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3296335-envision-shakes-up-management-to-buy-back-250m-in-shares-investors-unmoved-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296336\" data-ts=\"1505834450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRCM\" target=\"_blank\">CRCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296336-care-com-announces-new-independent-board-director\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Care.com announces new independent board director</a></h4><ul><li>        Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) <a href=\"https://seekingalpha.com/pr/16943936-care-com-appoints-george-bell-board-directors-lead-independent-director\" target=\"_blank\">announces</a> appointing George Bell as the lead independent director of its board.</li><li>               Bell was formerly the CEO of Jumtap, which sold to Millennial Media, and Upromise, which sold to Sallie Mae.&nbsp;</li><li>               Care.com shares are&nbsp;<font color='red'>down 2.06%</font>.&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296336\" data-linked=\"Care.com announces new independent board director\" data-tweet=\"$CRCM - Care.com announces new independent board director https://seekingalpha.com/news/3296336-care-com-announces-new-independent-board-director?source=tweet\" data-url=\"https://seekingalpha.com/news/3296336-care-com-announces-new-independent-board-director\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296304\" data-ts=\"1505833230\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296304-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+18%</font>. EBIO <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BLFS' title='BioLife Solutions, Inc.'>BLFS</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CLSN' title='Celsion Corporation'>CLSN</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296304\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CAPR $NBRV $SESN - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3296304-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3296304-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296329\" data-ts=\"1505833184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTAP\" target=\"_blank\">NTAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296329-ubs-upgrades-netapp-increases-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS upgrades NetApp, increases price target</a></h4><ul><li>        UBS <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+UBS+Upgrades+NetApp+%28NTAP%29+to+Buy/13307019.html\" target=\"_blank\">upgrades</a> NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>) from Neutral to Buy and increases the price target by $3 to $45.</li><li>               Analyst Steven Milunovich thinks &ldquo;post-earnings worries about services weakness will prove overdone given product sales acceleration.&rdquo;&nbsp;</li><li>               The analyst believes product gross margin will increase as discounting decreases and this will push earnings over consensus for FY18 through FY20.&nbsp;</li><li>               Milunovich has confidence in NetApp management and finds the risk/reward balance attractive.&nbsp;</li><li>               NetApp shares are&nbsp;<font color='green'>up 3.3%.</font>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296329\" data-linked=\"UBS upgrades NetApp, increases price target\" data-tweet=\"$NTAP - UBS upgrades NetApp, increases price target https://seekingalpha.com/news/3296329-ubs-upgrades-netapp-increases-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3296329-ubs-upgrades-netapp-increases-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296327\" data-ts=\"1505832783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296327-vale-says-to-meet-debt-target-implementing-new-growth-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale says to meet debt target before implementing new growth plans</a></h4><ul>     <li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-2.4%</font>) says its new growth strategy now being evaluated only will be implemented <a href=\"http://www.reuters.com/article/brazil-mining-vale-sa/brazils-vale-to-meet-debt-target-before-implementing-new-growth-plans-exec-idUSE4N1KW00S\" target=\"_blank\">once it meets its debt reduction targets</a>, an executive director of the iron ore producer says.</li>     <li>Vale also is interested in investing in the electricity sector itself or through a joint venture, including potentially bidding for Cemig (<a href='https://seekingalpha.com/symbol/CIG' title='Companhia Energtica de Minas Gerais - CEMIG'>CIG</a> <font color='red'>-1.9%</font>) hydroelectric projects, director Clovis Torres says.</li>     <li>Separately, reports from Bradesco BBI, Itau BBA and Banco Santander, citing meetings with Vale CEO Fabio Schvartsman, say there is room for further capex  reduction and cost improvement initiatives (source:&nbsp;Bloomberg First Word).</li>     <li>Schvartsman highlighted that the lack of internal coordination was a major issue for Vale, but management reorganization was one of the solutions to tackle this  problem and it is already yielding operational and commercial gains, according to Bradesco BBI&rsquo;s report.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296327\" data-linked=\"Vale says to meet debt target before implementing new growth plans\" data-tweet=\"$VALE $VALE $CIG - Vale says to meet debt target before implementing new growth plans https://seekingalpha.com/news/3296327-vale-says-to-meet-debt-target-implementing-new-growth-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3296327-vale-says-to-meet-debt-target-implementing-new-growth-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296326\" data-ts=\"1505832756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296326-long-term-forecast-from-best-buy-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Long-term forecast from Best Buy disappoints</a></h4><ul> <li>Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) swings lower after guidance issued by the company ahead of an investor day presentation disappoints.</li> <li>The retailer forecasts FY21 EPS of $4.75 to $5.00, enterprise revenue of $43B and operating income of $1.9B to $2.0B. There aren't consensus marks yet for earnings out four years, but the numbers from Best Buy imply an extended battle on pricing, notes Bloomberg Intelligence.</li><li>Shares of Best Buy are&nbsp;<font color='red'>down 8.75%</font>&nbsp;to wipe out the gains piled up since May.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3296286-best-buy-investor-day-preview\" target=\"_blank\">Best Buy investor day preview</a> (Sept. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296326\" data-linked=\"Long-term forecast from Best Buy disappoints\" data-tweet=\"$BBY - Long-term forecast from Best Buy disappoints https://seekingalpha.com/news/3296326-long-term-forecast-from-best-buy-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3296326-long-term-forecast-from-best-buy-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296319\" data-ts=\"1505831465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SINA\" target=\"_blank\">SINA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296319-sina-confirms-smacks-down-investor-board-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sina confirms, smacks down investor board demand</a></h4><ul><li>        Sina (NASDAQ:<a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a>) <a href=\"https://seekingalpha.com/pr/16944012-sina-confirms-receipt-nominations-aristeia-capital\" target=\"_blank\">confirms</a> that Aristeia Capital submitted a notice of nomination for the potential election of two board members during the annual meeting.</li><li>               Sina says &ldquo;Aristeia has decided to commence a self-serving campaign to place two of its nominees&rdquo; on the board and that the nominees have &ldquo;flatly refused&rdquo; interview requests by Sina&rsquo;s existing board. Sina alleges the investor, which owns a 3.5%, threatened a proxy fight if the nominees weren&rsquo;t approved &ldquo;blindly.&rdquo;&nbsp;</li><li>               Sina continues that the board examined the candidates as well as possible and found the candidates wouldn&rsquo;t add anything unique to the board.&nbsp;</li><li>               Sina shares are&nbsp;<font color='green'>up 1.9%.</font>&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296319\" data-linked=\"Sina confirms, smacks down investor board demand\" data-tweet=\"$SINA - Sina confirms, smacks down investor board demand https://seekingalpha.com/news/3296319-sina-confirms-smacks-down-investor-board-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3296319-sina-confirms-smacks-down-investor-board-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296315\" data-ts=\"1505830321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296315-foot-locker-weak-after-nike-ua-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker weak after Nike, UA downgrades</a></h4><ul> <li>Biting downgrades on Under Armour and Nike aren't going unnoticed by investors looking at Foot Locker (NYSE:<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a>).</li> <li>Shares of Foot Locker are&nbsp;<font color='red'>down 1.21%</font>&nbsp;on the day and are now off 52% for the last six months. The retailer often takes on collateral damage when footwear companies stumble.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3296239-wells-fargo-sees-earnings-dragging-armour\" target=\"_blank\">Wells Fargo sees earnings dragging at Under Armour</a> (Sept. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296282-susquehanna-warns-basketball-headaches-nike\" target=\"_blank\">Susquehanna warns on basketball headaches for Nike</a> (Sept. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296315\" data-linked=\"Foot Locker weak after Nike, UA downgrades\" data-tweet=\"$FL - Foot Locker weak after Nike, UA downgrades https://seekingalpha.com/news/3296315-foot-locker-weak-after-nike-ua-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3296315-foot-locker-weak-after-nike-ua-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296314\" data-ts=\"1505829903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGR\" target=\"_blank\">PGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296314-progressives-august-numbers-better-hoped-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progressive&#39;s August numbers better than hoped; shares up 3%</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/filing/3700685\" target=\"_blank\">incurred only about</a> $254M, or 12.6 loss ratio points from catastrophe losses in August vs. $75M a year ago. Just over 90% of total cat losses were due to Harvey.</li><li>Operating loss for the month of just $0.02 per share blew away estimates for losses of more than $0.30.</li><li><a href='https://seekingalpha.com/symbol/PGR' title='Progressive Corporation'>PGR</a>&nbsp;<font color='green'>+3%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3296314\" data-linked=\"Progressive&#39;s August numbers better than hoped; shares up 3%\" data-tweet=\"$PGR - Progressive&#39;s August numbers better than hoped; shares up 3% https://seekingalpha.com/news/3296314-progressives-august-numbers-better-hoped-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3296314-progressives-august-numbers-better-hoped-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296313\" data-ts=\"1505829786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLCO\" target=\"_blank\">MLCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296313-melco-resorts-rallies-after-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Melco Resorts rallies after upgrade</a></h4><ul> <li>Melco Resorts &amp; Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited ADR'>MLCO</a>) <font color='green'>jumps 3.24%</font> after Nomura Instinet lifts the casino stock to a Buy rating from Neutral.</li> <li>Closely-watched analyst Harry Curtis points to the EBITDA upside for Melco's City of Dreams and Studio City properties.</li> <li>New estimates from Curtis on Melco's EBITDA are enough to lift his price target to <a href=\"https://www.streetinsider.com/Analyst+Comments/NomuraInstinet+Upgrades+Melco+Resorts+%26+Entertainment+Limited+%28MLCO%29+to+Buy+Citing+Possible+Property+EBITDA+Multiple+Expansion+%26+Macau+Improvement/13306878.html\" target=\"_blank\">$29</a>.</li> <li>Shares of MLCO have ranged from $14.89 to $23.94 over the last 52 weeks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296313\" data-linked=\"Melco Resorts rallies after upgrade\" data-tweet=\"$MLCO - Melco Resorts rallies after upgrade https://seekingalpha.com/news/3296313-melco-resorts-rallies-after-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3296313-melco-resorts-rallies-after-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296308\" data-ts=\"1505829563\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296308-sprintplus-4_2-t-mobileplus-1_6-on-report-of-active-merger-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint +4.2%, T-Mobile +1.6% on report of active merger talks</a></h4><ul>     <li>Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) has <font color='green'>jumped 4.2%</font> to the $8 mark, and T-Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/TMUS' title='T-Mobile US, Inc.'>TMUS</a>) has <font color='green'>spiked 1.6%</font>, on reports that the two are in active talks about a merger.</li>     <li>That comes after some very quiet weeks following the FCC auction quiet period.</li>   <li>In the potential deal, <a href=\"https://www.cnbc.com/2017/09/19/t-mobile-and-sprint-are-in-active-talks-about-a-merger.html\" target=\"_blank\">according to CNBC</a>, it would be a stock-for-stock combination with Deutsche Telekom (<a href='https://seekingalpha.com/symbol/DTEGY' title='Deutsche Telekom AG ADR'>OTCQX:DTEGY</a>) emerging as the majority owner over SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>).</li><li>T-Mobile CEO John Legere would be expected to lead any combination, but SoftBank's Masayoshi Son would want a say in how the company's run.</li><li>The two haven't set an exchange ratio but are in talks to set a term sheet now, CNBC&nbsp;says. T-Mobile hasn't begun due diligence on Sprint.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296308\" data-linked=\"Sprint +4.2%, T-Mobile +1.6% on report of active merger talks\" data-tweet=\"$S $S $TMUS - Sprint +4.2%, T-Mobile +1.6% on report of active merger talks https://seekingalpha.com/news/3296308-sprintplus-4_2-t-mobileplus-1_6-on-report-of-active-merger-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3296308-sprintplus-4_2-t-mobileplus-1_6-on-report-of-active-merger-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>110&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296292\" data-ts=\"1505827157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZO\" target=\"_blank\">AZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296292-autozone-positive-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AutoZone positive on earnings beat</a></h4><ul>     <li>AutoZone (NYSE:<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc'>AZO</a>) reports domestic same-store sales rose 1% in <a href=\"https://seekingalpha.com/pr/16944187-autozone-4th-quarter-store-sales-increase-1_0-percent-4th-quarter-eps-increases-6_8-percent\" target=\"_blank\">Q4</a>.</li>     <li>Total auto parts sales increased 3.5% to $3.4B.</li>     <li>Total domestic commercial sales expanded 5.9% to $672.48M.</li>     <li>Gross profit rate fell 2 bps to 52.8% due tohigher supply chain costs (-16 bps) associated with current year inventory initiatives.</li>     <li>Inventory +6.9% Y/Y to $3.88B.</li>     <li>Domestic store count +168 Y/Y to 5,465.</li>     <li>Store count +215 Y/Y to 6,029.</li>     <li>AZO&nbsp;<font color='green'>+0.99%</font>&nbsp;premarket.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3296292\" data-linked=\"AutoZone positive on earnings beat\" data-tweet=\"$AZO - AutoZone positive on earnings beat https://seekingalpha.com/news/3296292-autozone-positive-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3296292-autozone-positive-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296290\" data-ts=\"1505827001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDX\" target=\"_blank\">ALDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296290-aldeyra-prices-equity-offering-shares-down-18-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aldeyra prices equity offering, shares down 18% premarket</a></h4><ul><li>Aldeyra Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>) slumps&nbsp;<font color='red'>18%</font>&nbsp;premarket on robust volume in response to the <a href=\"https://seekingalpha.com/pr/16944618-aldeyra-therapeutics-inc-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 3.45M shares of common stock at $7.25 per share. Underwriters over-allotment is an additional 517.5K shares. Closing date is September 21.</li><li>Net proceeds will fund the continued development of ADX-102, debt service, working capital and general corporate purposes.</li><li>Yesterday's close was $9.10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296290\" data-linked=\"Aldeyra prices equity offering, shares down 18% premarket\" data-tweet=\"$ALDX - Aldeyra prices equity offering, shares down 18% premarket https://seekingalpha.com/news/3296290-aldeyra-prices-equity-offering-shares-down-18-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296290-aldeyra-prices-equity-offering-shares-down-18-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296289\" data-ts=\"1505826851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296289-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>&nbsp;<font color='red'>-27%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3296268-synchronoss-18_8-percent-buyout-offer-snag\" target=\"_blank\">buyout</a> offer snag.</li><li><a href='https://seekingalpha.com/symbol/ALDX' title='Aldeyra Therapeutics, Inc.'>ALDX</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296156-aldeyra-readies-equity-offering-shares-7-percent-hours\" target=\"_blank\">announcing</a> proposed public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a>&nbsp;<font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296234-mediwound-prices-public-offering-4_4m-ordinary-shares-offering-5-shares-15-percent-premarket\" target=\"_blank\">pricing</a> public offering of 4.4M ordinary shares.</li><li><a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296277-mcewen-mining-minus-10-percent-following-40m-bought-deal-financing\" target=\"_blank\">announcing</a> bought out deal of $40.5M.</li><li><a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>&nbsp;<font color='red'>-8%</font>&nbsp;on FTC <a href=\"https://seekingalpha.com/news/3296259-u-s-ftc-signs-walgreens-rite-aid-deal\" target=\"_blank\">clearing</a> Walgreens/Rite Aid deal.</li><li><a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/VGR' title='Vector Group Ltd.'>VGR</a> <font color='red'>-7%</font>.</li><li>ITUS <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3296289\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$SNCR $ALDX $MDWD - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3296289-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3296289-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296288\" data-ts=\"1505826759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296288-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+8%.</font></li>     <li><a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics'>NBRV</a> <font color='green'>+7%</font>&nbsp;on equity&nbsp;<a href=\"https://seekingalpha.com/news/3296173-nabriva-readies-equity-offering-shares-5-percent-hours\" target=\"_blank\">offering</a>&nbsp;of $80M shares.</li>     <li><a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296237-premarket-analyst-action-healthcare-coverage-changes\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/BOBE' title='Bob Evans Farms, Inc.'>BOBE</a> <font color='green'>+6%</font>&nbsp;as investors <a href=\"https://seekingalpha.com/news/3296267-investors-bid-bob-evans-farms-past-post-deal-price\" target=\"_blank\">bid</a> up Bob Evans Farms.</li>     <li><a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3296235-premarket-analyst-action-healthcare-new-coverage\" target=\"_blank\">positive</a> analyst action.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296288\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CAPR $NBRV $ADMS - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3296288-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3296288-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296285\" data-ts=\"1505826400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296285-portola-pharma-slips-5-premarket-on-feuerstein-article-citing-risk-to-bevyxxa-sales-from-new\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharma slips 5% premarket on Feuerstein article citing risk to Bevyxxa sales from new usage guidelines</a></h4><ul><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) is down<font color='red'> 5%</font>&nbsp;premarket on modest volume on the heels of a new <a href=\"https://www.statnews.com/2017/09/19/portola-launch-threatened/\" target=\"_blank\">article </a>by STAT News' Adam Feuerstein who says the market launch of recently approved BEVYXXA (betrixaban), an extended-duration anticoagulant, could be hampered by new clinical guidelines against a new use for the blood thinners.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3275322-fda-oks-portolas-anticoagulant-betrixaban-shares-1-percent\" target=\"_blank\">FDA OKs Portola's anticoagulant betrixaban; shares up 1%</a> (June 23)</li><li><strong>Update</strong>: According to Oppenheimer's Jay Olson, the draft guidelines, published on July 25, included a recommendation against using an entire group of anticoagulants for extended prophylaxis, not Bevyxxa specifically. The recommendation was based on a pooled analysis across several studies. PTLA is down&nbsp;<font color='red'>8%</font>&nbsp;on more than 4x higher volume near the close.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3296285\" data-linked=\"Portola Pharma slips 5% premarket on Feuerstein article citing risk to Bevyxxa sales from new usage guidelines\" data-tweet=\"$PTLA - Portola Pharma slips 5% premarket on Feuerstein article citing risk to Bevyxxa sales from new usage guidelines https://seekingalpha.com/news/3296285-portola-pharma-slips-5-premarket-on-feuerstein-article-citing-risk-to-bevyxxa-sales-from-new?source=tweet\" data-url=\"https://seekingalpha.com/news/3296285-portola-pharma-slips-5-premarket-on-feuerstein-article-citing-risk-to-bevyxxa-sales-from-new\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296284\" data-ts=\"1505826283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEIX\" target=\"_blank\">PEIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296284-pacific-ethanol-extends-gains-after-refinancing-promissory-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Ethanol extends gains after refinancing promissory notes</a></h4><ul>     <li>Pacific Ethanol (NASDAQ:<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a>) <font color='green'>+2.8%</font> premarket following yesterday's 3.8% boost as it <a href=\"https://seekingalpha.com/pr/16943117-pacific-ethanol-refinances-47_5-million-secured-promissory-notes\" target=\"_blank\">refinanced</a> $47.5M in secured promissory notes tied to its <a href=\"https://seekingalpha.com/news/3275688-pacific-ethanol-buys-illinois-corn-processing-76m\" target=\"_blank\">June acquisition</a> of Illinois Corn Processing.</li>     <li>To repay the notes, PEIX used $6M of cash on hand and $42M in proceeds from new term and revolving debt financing with CoBank.</li>     <li>\"With the CoBank term loan and revolving credit facility, we further strengthen our balance sheet with lower cost and longer-term debt,\" CEO Neil Koehler said yesterday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296284\" data-linked=\"Pacific Ethanol extends gains after refinancing promissory notes\" data-tweet=\"$PEIX - Pacific Ethanol extends gains after refinancing promissory notes https://seekingalpha.com/news/3296284-pacific-ethanol-extends-gains-after-refinancing-promissory-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/3296284-pacific-ethanol-extends-gains-after-refinancing-promissory-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296282\" data-ts=\"1505826203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296282-susquehanna-warns-on-basketball-headaches-for-nike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna warns on basketball headaches for Nike</a></h4><ul> <li>Susuquehanna lowers Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) to a Neutral rating from Buy on mounting concerns over weakness in the business.</li> <li>The firm thinks the basketball category is a particular concern and could see excess inventory due to a lack of momentum (<a href=\"https://seekingalpha.com/news/3296122-adidas-stuns-basketball-shoes-momentum\" target=\"_blank\">see Adidas basketball momentum</a>).</li> <li>Analyst Sam Poser lowers his estimates on Nike to FY18 F/X-neutral revenue growtt of +3.3% from +4.5%. The estimate on FY19 revenue goes down to +6.1% from +9.1%.</li> <li>NKE <font color='red'>-1.50%</font> premarket to $52.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296282\" data-linked=\"Susquehanna warns on basketball headaches for Nike\" data-tweet=\"$NKE - Susquehanna warns on basketball headaches for Nike https://seekingalpha.com/news/3296282-susquehanna-warns-on-basketball-headaches-for-nike?source=tweet\" data-url=\"https://seekingalpha.com/news/3296282-susquehanna-warns-on-basketball-headaches-for-nike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296279\" data-ts=\"1505825529\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296279-amicus-therapeutics-migalastat-fast-trackd-in-u-s-for-fabry-disease-shares-ahead-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus Therapeutics&#39; migalastat Fast Track&#39;d in U.S. for Fabry disease; shares ahead 2% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16944288-u-s-fda-grants-fast-track-designation-amicus-therapeutics-migalastat-treatment-fabry-disease\" target=\"_blank\">designates</a> Amicus Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) migalastat (Galafold) for Fast Track review for the treatment of patient with Fabry disease with amenable mutations. The company expects to file an NDA in Q4.</li><li>Fabry, an inherited lysosomal storage disorder caused by an enzyme deficiency, is characterized by the accumulation of certain lipids in tissues that leads to kidney failure, heart disease and stroke.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296279\" data-linked=\"Amicus Therapeutics&#39; migalastat Fast Track&#39;d in U.S. for Fabry disease; shares ahead 2% premarket\" data-tweet=\"$FOLD - Amicus Therapeutics&#39; migalastat Fast Track&#39;d in U.S. for Fabry disease; shares ahead 2% premarket https://seekingalpha.com/news/3296279-amicus-therapeutics-migalastat-fast-trackd-in-u-s-for-fabry-disease-shares-ahead-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296279-amicus-therapeutics-migalastat-fast-trackd-in-u-s-for-fabry-disease-shares-ahead-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296277\" data-ts=\"1505825025\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MUX\" target=\"_blank\">MUX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296277-mcewen-miningminus-10-following-40m-bought-deal-financing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McEwen Mining -10% following $40M bought deal financing</a></h4><ul>     <li>McEwen Mining (NYSE:<a href='https://seekingalpha.com/symbol/MUX' title='McEwen Mining Inc.'>MUX</a>) <font color='red'>-9.9%</font> premarket after announced after the close yesterday a <a href=\"https://seekingalpha.com/pr/16943911-mcewen-mining-announces-bought-deal-40_5-million\" target=\"_blank\">$40.5M bought deal financing</a> for its recent <a href=\"https://seekingalpha.com/news/3292540-mcewen-mining-buys-black-fox-complex-primero-mining\" target=\"_blank\">acquisition</a> of&nbsp;the Black Fox mining complex in Ontario.</li>     <li>MUX agrees to sell 18M common shares and warrants to purchase as many as 9M common shares at $2.25 each and associated one-half stock warrant for $40.5M in gross proceeds, with an underwriters option to buy an additional 2.7M shares and 1.35M warrants.</li>     <li>MUX's $35M Black Fox acquisition from&nbsp;Primero Mining&nbsp;announced last month was its second deal this year involving the Timmins gold camp.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296277\" data-linked=\"McEwen Mining -10% following $40M bought deal financing\" data-tweet=\"$MUX - McEwen Mining -10% following $40M bought deal financing https://seekingalpha.com/news/3296277-mcewen-miningminus-10-following-40m-bought-deal-financing?source=tweet\" data-url=\"https://seekingalpha.com/news/3296277-mcewen-miningminus-10-following-40m-bought-deal-financing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296266\" data-ts=\"1505824928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRQR\" target=\"_blank\">PRQR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296266-proqr-receives-odd-from-fda-for-qrminus-313-for-deb-and-will-present-data-two-scientific\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProQR receives ODD from FDA for QR-313 for DEB and will present data at two scientific conferences; shares ahead 8% premarket</a></h4><ul><li>ProQR Therapeutics N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a>) <a href=\"https://seekingalpha.com/pr/16944204-proqr-receives-orphan-drug-designation-fda-drug-candidate-qrminus-313-dystrophic\" target=\"_blank\">announces</a> that investigational drug <a href=\"http://www.proqr.com/qr-313-for-dystrophic-epidermolysis-bullosa/\" target=\"_blank\">QR-313</a>, a&nbsp;RNA-based oligonucleotide designed to address the cause in <a href=\"https://en.wikipedia.org/wiki/Epidermolysis_bullosa_dystrophica\" target=\"_blank\">dystrophic epidermolysis bullosa</a> &#40;DEB&#41; due to mutations in exon 73 of the COL7A1 gene, has been designated an Orphan Drug by the FDA, its fifth.</li><li>The Company will be presenting pre-clinical data for QR-313 at two European scientific conferences in&nbsp;Salzburg, Austria&nbsp;&ndash; EB2017 Research Conference and ESDR Meeting.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296266\" data-linked=\"ProQR receives ODD from FDA for QR-313 for DEB and will present data at two scientific conferences; shares ahead 8% premarket\" data-tweet=\"$PRQR - ProQR receives ODD from FDA for QR-313 for DEB and will present data at two scientific conferences; shares ahead 8% premarket https://seekingalpha.com/news/3296266-proqr-receives-odd-from-fda-for-qrminus-313-for-deb-and-will-present-data-two-scientific?source=tweet\" data-url=\"https://seekingalpha.com/news/3296266-proqr-receives-odd-from-fda-for-qrminus-313-for-deb-and-will-present-data-two-scientific\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296268\" data-ts=\"1505824197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296268-synchronoss-down-18_8-after-buyout-offer-snag\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss down 18.8% after buyout offer snag</a></h4><ul><li>        Synchronoss Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) shares&nbsp;<font color='red'>down 18.81%&nbsp;</font>premarket after Siris Capital Group says it&rsquo;s no longer interested in an <a href=\"http://www.marketwatch.com/story/synchronosss-stock-plunges-after-siris-ends-buyout-interest-2017-09-19\" target=\"_blank\">all-cash buyout</a> of the company.</li><li>                  Siris Capital Group still owns 13% of Synchronoss shares outstanding and says it will consider other transaction types.    </li><li>               Synchronoss statement: &ldquo;The Synchronoss board is committed to enhancing value for all shareholders and continues to explore a full range of strategic, operational and financial alternatives, which may include a sale of the company or other transactions.&rdquo;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3296268\" data-linked=\"Synchronoss down 18.8% after buyout offer snag\" data-tweet=\"$SNCR - Synchronoss down 18.8% after buyout offer snag https://seekingalpha.com/news/3296268-synchronoss-down-18_8-after-buyout-offer-snag?source=tweet\" data-url=\"https://seekingalpha.com/news/3296268-synchronoss-down-18_8-after-buyout-offer-snag\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296263\" data-ts=\"1505823870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMTX\" target=\"_blank\">DMTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296263-dimension-board-says-ultragenyx-bid-be-superior-to-regenxbio-offer-discussions-to-proceed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dimension board says Ultragenyx bid could be &quot;superior&quot; to REGENXBIO offer, discussions to proceed; shares slip 4% premarket</a></h4><ul><li>The board of Dimension Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a>) has <a href=\"https://seekingalpha.com/pr/16944350-dimension-board-directors-determines-proposal-ultragenyx-pharmaceutical-inc-reasonably\" target=\"_blank\">determined </a>that Ultragenyx Pharmaceutical's (NASDAQ:<a href='https://seekingalpha.com/symbol/RARE' title='Ultragenyx Pharmaceutical Inc.'>RARE</a>) unsolicited cash bid of $5.50 per share could reasonably be expected to lead to a \"superior proposal\" under the terms of its merger agreement with REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO'>RGNX</a>). As such, discussions will proceed with Ultragenyx.&nbsp;Dimension says it will not comment further until the negotiations have been completed.</li><li>DMTX shares are down&nbsp;<font color='red'>4%</font>&nbsp;premarket after Citigroup issued a Sell rating citing a low probability of another bid topping RARE's. Shares closed yesterday at $5.90.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296035-ultragenyx-makes-138m-cash-offer-dimension-therapeutics-trumps-regenxbios-stock-deal\" target=\"_blank\">Ultragenyx makes $138M cash offer for Dimension Therapeutics, trumps REGENXBIO's all-stock deal</a> (Sept. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291791-regenxbio-acquire-dimension-therapeutics-stock-deal-dimension-163-percent-premarket\" target=\"_blank\">REGENXBIO to acquire Dimension Therapeutics in all-stock deal, Dimension up 163% premarket</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3296263\" data-linked=\"Dimension board says Ultragenyx bid could be &quot;superior&quot; to REGENXBIO offer, discussions to proceed; shares slip 4% premarket\" data-tweet=\"$DMTX $DMTX $RARE - Dimension board says Ultragenyx bid could be &quot;superior&quot; to REGENXBIO offer, discussions to proceed; shares slip 4% premarket https://seekingalpha.com/news/3296263-dimension-board-says-ultragenyx-bid-be-superior-to-regenxbio-offer-discussions-to-proceed?source=tweet\" data-url=\"https://seekingalpha.com/news/3296263-dimension-board-says-ultragenyx-bid-be-superior-to-regenxbio-offer-discussions-to-proceed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296262\" data-ts=\"1505823852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296262-credit-suisse-warms-up-to-gap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse warms up to Gap</a></h4><ul> <li>Gap (NYSE:<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a>) is higher in early action after Credit Suisse lifts its rating to Neutral from Underperform. The firm notes the recent improvements in Gap's supply chain and cites the attractive valuation.</li> <li>CS hikes its price target up to $30 from $23.</li> <li>GPS <font color='green'>+2.15%</font> premarket to $28.50. Shares are up 22% over the last 90 days.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296262\" data-linked=\"Credit Suisse warms up to Gap\" data-tweet=\"$GPS - Credit Suisse warms up to Gap https://seekingalpha.com/news/3296262-credit-suisse-warms-up-to-gap?source=tweet\" data-url=\"https://seekingalpha.com/news/3296262-credit-suisse-warms-up-to-gap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296261\" data-ts=\"1505823506\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAT\" target=\"_blank\">MAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296261-toy-stocks-react-to-toys-r-us-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toy stocks react to Toys &quot;R&quot; Us bankruptcy</a></h4><ul> <li>Shares of Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) are <font color='green'>up 0.77%</font> in early trading after the Toys \"R\" Us bankruptcy becomes official.</li> <li>Investors have been selling off Mattel ahead of the news due to the expected disruption ahead of the holiday season.</li> <li>Hasbro (NASDAQ:<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>) is <font color='red'>down 0.90%</font>.</li><li>Spin Master (<a href='https://seekingalpha.com/symbol/SNMSF' title='SPIN MASTER CORP'>OTC:SNMSF</a>)&nbsp;and JAKKS Pacific (NASDAQ:<a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a>)&nbsp;could also see some extra volatility today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296197-toys-r-us-files-bankruptcy\" target=\"_blank\">Toys 'R' Us files for bankruptcy</a> (Sept. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296261\" data-linked=\"Toy stocks react to Toys &quot;R&quot; Us bankruptcy\" data-tweet=\"$MAT $MAT $HAS - Toy stocks react to Toys &quot;R&quot; Us bankruptcy https://seekingalpha.com/news/3296261-toy-stocks-react-to-toys-r-us-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3296261-toy-stocks-react-to-toys-r-us-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296250\" data-ts=\"1505822428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296250-fda-oks-glaxos-inhaled-triplet-therapy-for-copd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Glaxo&#39;s inhaled triplet therapy for COPD</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16943987-trelegy-ellipta-approved-first-daily-single-inhaler-triple-therapy-treatment-appropriate\" target=\"_blank\">approves </a>GlaxoSmithKline's (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) Trelegy Ellipta [fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)], a once-daily, single inhaler triplet therapy for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease &#40;COPD&#41;, including chronic bronchitis and/or emphysema. Market launch will commence shortly.</li><li>Glaxo developed the product with collaboration partner Innoviva (NASDAQ:<a href='https://seekingalpha.com/symbol/INVA' title='Innoviva, Inc.'>INVA</a>). Approval in Europe should happen in Q4.</li><li>INVA is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296250\" data-linked=\"FDA OKs Glaxo&#39;s inhaled triplet therapy for COPD\" data-tweet=\"$GSK $GSK $INVA - FDA OKs Glaxo&#39;s inhaled triplet therapy for COPD https://seekingalpha.com/news/3296250-fda-oks-glaxos-inhaled-triplet-therapy-for-copd?source=tweet\" data-url=\"https://seekingalpha.com/news/3296250-fda-oks-glaxos-inhaled-triplet-therapy-for-copd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296237\" data-ts=\"1505820880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCK\" target=\"_blank\">MCK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296237-premarket-analyst-action-healthcare-coverage-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare coverage changes</a></h4><ul><li>McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>) upgraded to Outperform with a $178 (20% upside) price target by Baird citing attractive valuation.</li><li>Quidel (NASDAQ:<a href='https://seekingalpha.com/symbol/QDEL' title='Quidel Corporation'>QDEL</a>) upgraded to Overweight by Piper Jaffray.</li><li>Supernus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SUPN' title='Supernus Pharmaceuticals, Inc.'>SUPN</a>) downgraded to Hold with a $47 (5% downside risk) price target by Stifel citing valuation and risk in the Phase 3 study of SPN-810 since lower dose eliminated.</li><li>Adamas Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMS' title='Adamas Pharmaceuticals, Inc.'>ADMS</a>) price target raised to $48 (129% upside) by Mizuho citing higher-than-expected Gocovri pricing and higher estimates for MS gait program, although launch expectations in 2018 lowered after conservative guidance.</li><li>Dimension Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a>) downgraded to Sell by Citigroup citing a \"small chance\" of a higher bid topping Ultragenyx Pharma's $5.50/share offer. Shares are down&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3296237\" data-linked=\"Premarket analyst action - healthcare coverage changes\" data-tweet=\"$MCK $MCK $QDEL - Premarket analyst action - healthcare coverage changes https://seekingalpha.com/news/3296237-premarket-analyst-action-healthcare-coverage-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/3296237-premarket-analyst-action-healthcare-coverage-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296234\" data-ts=\"1505820420\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDWD\" target=\"_blank\">MDWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296234-mediwound-prices-public-offering-of-4_4m-ordinary-shares-offering-5-shares-off-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediWound prices public offering of 4.4M ordinary shares offering at $5; shares off 15% premarket</a></h4><ul> <li>MediWound (NASDAQ:<a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a>) <a href=\"https://seekingalpha.com/pr/16944167-mediwound-ltd-announces-pricing-22-million-public-offering-ordinary-shares\" target=\"_blank\">prices</a> an underwritten public offering of 4.4M of its ordinary shares at a price of $5.00 per share yielding in gross proceeds of $22M.</li><li>Underwriters over-allotment is an additional 660K shares.</li><li>Closing date is September 21.</li><li>Shares are down&nbsp;<font color='red'>15%</font>&nbsp;premarket on light volume. Yesterday's close was $6.05.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3296234\" data-linked=\"MediWound prices public offering of 4.4M ordinary shares offering at $5; shares off 15% premarket\" data-tweet=\"$MDWD - MediWound prices public offering of 4.4M ordinary shares offering at $5; shares off 15% premarket https://seekingalpha.com/news/3296234-mediwound-prices-public-offering-of-4_4m-ordinary-shares-offering-5-shares-off-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3296234-mediwound-prices-public-offering-of-4_4m-ordinary-shares-offering-5-shares-off-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3296226\" data-ts=\"1505818840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3296226-michael-kors-higher-after-oppenheimer-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Michael Kors higher after Oppenheimer upgrade</a></h4><ul> <li>Oppenheimer upgrades Michael Kors (KORS) to an Outperform rating after having the stock set at Market Perform.</li> <li>Analyst Anna Andreeva notes that margins at MK appear to have hit a bottom and is impressed with the full price sell rate on products. The addition of the Jimmy Choo business is also seen as an earnings driver.</li> <li>The price target goes to $55 from $44 to rep 23% upside potential. Shares of Michael Kors are <font color='green'>up 2.58%</font> in premarket trading.</li><li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3296226\" data-linked=\"Michael Kors higher after Oppenheimer upgrade\" data-tweet=\"$CPRI - Michael Kors higher after Oppenheimer upgrade https://seekingalpha.com/news/3296226-michael-kors-higher-after-oppenheimer-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3296226-michael-kors-higher-after-oppenheimer-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM </div></div></li>","count":64,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}